Kindlin-2 modulates MafA and β-catenin expression to regulate β-cell function and mass in mice.
Ke ZhuYumei LaiHuiling CaoXiao-Chun BaiChuanju LiuQinnan YanLiting MaDi ChenGiedrius KanaporisJun-Qi WangLuyuan LiTao ChengYong WangChuanyue WuGuozhi XiaoPublished in: Nature communications (2020)
β-Cell dysfunction and reduction in β-cell mass are hallmark events of diabetes mellitus. Here we show that β-cells express abundant Kindlin-2 and deleting its expression causes severe diabetes-like phenotypes without markedly causing peripheral insulin resistance. Kindlin-2, through its C-terminal region, binds to and stabilizes MafA, which activates insulin expression. Kindlin-2 loss impairs insulin secretion in primary human and mouse islets in vitro and in mice by reducing, at least in part, Ca2+ release in β-cells. Kindlin-2 loss activates GSK-3β and downregulates β-catenin, leading to reduced β-cell proliferation and mass. Kindlin-2 loss reduces the percentage of β-cells and concomitantly increases that of α-cells during early pancreatic development. Genetic activation of β-catenin in β-cells restores the diabetes-like phenotypes induced by Kindlin-2 loss. Finally, the inducible deletion of β-cell Kindlin-2 causes diabetic phenotypes in adult mice. Collectively, our results establish an important function of Kindlin-2 and provide a potential therapeutic target for diabetes.
Keyphrases
- induced apoptosis
- type diabetes
- cell proliferation
- cell cycle arrest
- cardiovascular disease
- insulin resistance
- poor prognosis
- glycemic control
- oxidative stress
- epithelial mesenchymal transition
- cell therapy
- stem cells
- adipose tissue
- endoplasmic reticulum stress
- pi k akt
- early onset
- metabolic syndrome
- skeletal muscle
- bone marrow
- climate change
- polycystic ovary syndrome
- induced pluripotent stem cells